Literature DB >> 109469

Complement-dependent histaminase release from human granulocytes.

J J Herman, I K Rosner, A E Davis, R S Zeiger, M A Arnaout, H R Colten.   

Abstract

The role of particle-bound complement proteins in the induction of noncytotoxic enzyme release from human granulocytes was investigated with the use of sera genetically deficient in complement and highly purified complement components. Release of histaminase, one of two important histamine catabolizing enzymes, and beta-glucuronidase from polymorphonuclear leukocytes was solely dependent on particle-bound C3b (the larger cleavage product of the third component of complement) when fluid-phase complement was excluded. The extent of enzyme release was a function of particle-bound C3b input, was reduced by exposing the particles to C3b inactivator, and was blocked by fluid-phase C3b. Phagocytosis of the C3b-coated particles was not required for enzyme release from neutrophils. In contrast, phagocytosis of "opsonized" particles was required for noncytotoxic release of histaminase and arylsulfatase from eosinophils; other proteins, as well as C3b, were able to opsonize particles for induction of enzyme release from eosinophils. These studies suggest a dual role for complement (particularly C3) in modulating vascular permeability phenomena, i.e., release of vasoactive mediators by the action of C3a and C5a, and release of the corresponding enzymes that inactivate the mediators by C3b.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 109469      PMCID: PMC372068          DOI: 10.1172/JCI109414

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  27 in total

Review 1.  Complement.

Authors:  H J Müller-Eberhard
Journal:  Annu Rev Biochem       Date:  1975       Impact factor: 23.643

2.  Metalloenzymes and myocardial infarction. II. Malic and lactic dehydrogenase activities and zinc concentrations in serum.

Authors:  D D ULMER; B L VALLEE; W E WACKER
Journal:  N Engl J Med       Date:  1956-09-06       Impact factor: 91.245

3.  Homozygous deficiency of C3 in a patient with repeated infections.

Authors:  C A Alper; H R Colten; F S Rosen; A R Rabson; G M Macnab; J S Gear
Journal:  Lancet       Date:  1972-12-02       Impact factor: 79.321

4.  Inactivation of slow reacting substance of anaphylaxis by human eosinophil arylsulfatase.

Authors:  S I Wasserman; E J Goetzl; K F Austen
Journal:  J Immunol       Date:  1975-02       Impact factor: 5.422

5.  Restoration by purified C3b inactivator of complement-mediated function in vivo in a patient with C3b inactivator deficiency.

Authors:  J B Ziegler; C A Alper; R S Rosen; P J Lachmann; L Sherington
Journal:  J Clin Invest       Date:  1975-03       Impact factor: 14.808

6.  Human C3 and C5: subunit structure and modifications by trypsin and C42-C423.

Authors:  U R Nilsson; R J Mandle; J A McConnell-Mapes
Journal:  J Immunol       Date:  1975-02       Impact factor: 5.422

7.  Histaminase release from human eosinophils.

Authors:  R S Zeiger; H R Colten
Journal:  J Immunol       Date:  1977-02       Impact factor: 5.422

8.  ISOLATION OF BETA IF-GLOBULIN FROM HUMAN SERUM AND ITS CHARACTERIZATION AS THE FIFTH COMPONENT OF COMPLEMENT.

Authors:  U R NILSSON; H J MUELLER-EBERHARD
Journal:  J Exp Med       Date:  1965-08-01       Impact factor: 14.307

9.  THE ROLE OF SERUM COMPLEMENT IN CHEMOTAXIS OF LEUKOCYTES IN VITRO.

Authors:  P A WARD; C G COCHRANE; H J MUELLER-EBERHARD
Journal:  J Exp Med       Date:  1965-08-01       Impact factor: 14.307

10.  STUDIES ON THE MECHANISMS OF HYPERSENSITIVITY PHENOMENA. IX. HISTAMINE RELEASE FROM HUMAN LEUKOCYTES BY RAGWEED POLLEN ANTIGEN.

Authors:  L M LICHTENSTEIN; A G OSLER
Journal:  J Exp Med       Date:  1964-10-01       Impact factor: 14.307

View more
  9 in total

1.  Identification of C3 beta chain as the human serum eosinophil cytotoxicity inhibitor.

Authors:  M S Minkoff; W W Wong; D S Silberstein
Journal:  J Exp Med       Date:  1991-11-01       Impact factor: 14.307

2.  The role of complement in the stimulation of lysosomal enzyme release by polymorphonuclear leucocytes induced by immune complexes of IgG and of IgM.

Authors:  Y M Lucisano; B Mantovani
Journal:  Immunology       Date:  1988-10       Impact factor: 7.397

3.  C3b acceptors on human peripheral blood mononuclear cells; characterization and functional role.

Authors:  A Erdei; G Füst; J Gyenes; Z Fábry; J Gergely
Journal:  Immunology       Date:  1983-07       Impact factor: 7.397

4.  Pathogenic roles of eosinophils in guinea-pig contact sensitivity: regulation of dermal eosinophilia with remotely administered IL-5.

Authors:  T Satoh; H Yokozeki; K Nishioka
Journal:  Clin Exp Immunol       Date:  2000-12       Impact factor: 4.330

5.  Toxic effects of human eosinophil products on isolated rat heart cells in vitro.

Authors:  P C Tai; D J Hayes; J B Clark; C J Spry
Journal:  Biochem J       Date:  1982-04-15       Impact factor: 3.857

6.  Monoclonal antibodies to human eosinophil plasma membrane antigens enhance the secretion of eosinophil cationic protein.

Authors:  P C Tai; M Capron; D M Bakes; J Barkans; C J Spry
Journal:  Clin Exp Immunol       Date:  1986-03       Impact factor: 4.330

7.  Eosinophil diamine oxidase activity in acute inflammation in humans.

Authors:  J J Herman
Journal:  Agents Actions       Date:  1982-04

8.  Low zone desensitization: a stimulus-specific control mechanism of cell response. Investigations on anaphylatoxin-induced platelet secretion.

Authors:  S Meuer; B Zanker; U Hadding; D Bitter-Suermann
Journal:  J Exp Med       Date:  1982-03-01       Impact factor: 14.307

9.  Human diamine oxidase is readily released from activated neutrophils ex vivo and in vivo but is rarely elevated in bacteremic patients.

Authors:  Thomas Boehm; Matthias Karer; Peter Matzneller; Nina Buchtele; Franz Ratzinger; Karin Petroczi; Christian Schoergenhofer; Michael Schwameis; Heinz Burgmann; Markus Zeitlinger; Bernd Jilma
Journal:  Int J Immunopathol Pharmacol       Date:  2020 Jan-Dec       Impact factor: 3.219

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.